Chagas disease: Difference between revisions

Jump to navigation Jump to search
Line 42: Line 42:
==Treatment==
==Treatment==
[[Chagas disease medical therapy|Medical therapy]] | [[Chagas disease surgery|Surgical options]] | [[Chagas disease primary prevention|Primary prevention]]  | [[Chagas disease secondary prevention|Secondary prevention]] | [[Chagas disease cost-effectiveness of therapy|Financial costs]] | [[Chagas disease future or investigational therapies|Future therapies]]
[[Chagas disease medical therapy|Medical therapy]] | [[Chagas disease surgery|Surgical options]] | [[Chagas disease primary prevention|Primary prevention]]  | [[Chagas disease secondary prevention|Secondary prevention]] | [[Chagas disease cost-effectiveness of therapy|Financial costs]] | [[Chagas disease future or investigational therapies|Future therapies]]
==Prevention==
[[Image:Triatoma infestans.jpg|thumb|Vector insect ''[[Triatoma infestans]]'' (Kissing Bug)]]
A reasonably effective [[vaccine]] was developed in Ribeirão Preto in the 1970s, using cellular and subcellular fractions of the parasite, but it was found economically unfeasible. More recently, the potential of DNA vaccines for [[immunotherapy]] of acute and chronic Chagas' disease is being tested by several research groups.
Prevention is centered on fighting the vector (''Triatoma'') by using sprays and paints containing [[insecticide]]s (synthetic [[pyrethrum|pyrethroids]]), and improving housing and sanitary conditions in the rural area. For urban dwellers, spending vacations and camping out in the wilderness or sleeping at hostels or mud houses in endemic areas can be dangerous, a [[mosquito net]] is recommended. If the traveller intends to travel to the area of prevalence, he/she should get information on endemic rural areas for Chagas' disease in traveller advisories, such as the [[Centers for Disease Control and Prevention|CDC]].
In most countries where Chagas' disease is endemic, [[blood tests|testing]] of [[blood donation|blood donors]] is already mandatory, since this can be an important route of transmission. The United States FDA has recently licensed a test for antibodies against T. cruzi for use on blood donors but has not yet mandated its use.  The AABB recommends that past recipients of blood components from donors found to be infected be notified and themselves tested. 
In the past, donated blood was mixed with 0,25 g/L of [[gentian violet]] successfully to kill the parasites. Early detection and treatment of new cases, including mother-to-baby cases, will also help reduce the burden of disease.
With all these measures, some landmarks were achieved in the fight against Chagas' disease in Latin America: a reduction by 72% of the incidence of human infection in children and young adults in the countries of the Initiative of the Southern Cone, and at least two countries (Uruguay, in 1997, and Chile, in 1999), were certified free of vectorial and transfusional transmission. In Brazil, with the largest population at risk, 10 out of the 12 endemic states were also certified free.
Some stepstones of vector control:
*A yeast trap has been tested for monitoring infestations of certain species of the bugs:"Performance of yeast-baited traps with ''Triatoma sordida'', ''Triatoma brasiliensis'', ''Triatoma pseudomaculata'', and ''Panstrongylus megistus'' in laboratory assays."<ref>Pires HH, Lazzari CR, Diotaiuti L, Lorenzo MG. "Performance of yeast-baited traps with Triatoma sordida, Triatoma brasiliensis, Triatoma pseudomaculata, and Panstrongylus megistus in laboratory assays." Rev Panam Salud Publica. 2000 Jun;7(6):384-8. PMID 10949899</ref>
*Promising results were gained with the treatment of vector habitats with the fungus ''[[Beauveria bassiana]]'', (which is also in discussion for [[malaria]]- prevention):"Activity of oil-formulated ''Beauveria bassiana'' against ''Triatoma sordida'' in peridomestic areas in Central Brazil."<ref>Luz C, Rocha LF, Nery GV, Magalhaes BP, Tigano MS. "Activity of oil-formulated Beauveria bassiana against Triatoma sordida in peridomestic areas in Central Brazil." Mem Inst Oswaldo Cruz. 2004 Mar;99(2):211-8. PMID 15250478 [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762004000200017&tlng=es&lng=en&nrm=iso Online.]</ref>
*Targeting the [[symbiont]]s of [[Triatominae]] through [[paratransgenesis]].<ref>{{cite web|url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&db=PubMed&term=Triatominae%20symbiosis|title=PubMed Search on Triatominae symbiosis}}</ref>
==See also==
==See also==
*[[Tropical disease]]
*[[Tropical disease]]

Revision as of 15:21, 27 January 2012

Template:Featured article

Chagas disease
Photomicrograph of Giemsa-stained Trypanosoma cruzi crithidia (CDC)
ICD-10 B57
ICD-9 086
DiseasesDB 13415
MedlinePlus 001372
MeSH D014355

For patient information click here

Chagas disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chagas disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chagas disease On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chagas disease

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chagas disease

CDC on Chagas disease

Chagas disease in the news

Blogs on Chagas disease

Directions to Hospitals Treating Chagas disease

Risk calculators and risk factors for Chagas disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Pathophysiology

Epidemiology & Demographics

Risk Factors

Screening

Causes

Differentiating Chagas disease

Complications & Prognosis

Diagnosis

History and Symptoms | Physical Examination | Staging | Laboratory tests | Electrocardiogram | X Rays | CT | MRI Echocardiography or Ultrasound | Other images | Alternative diagnostics

Treatment

Medical therapy | Surgical options | Primary prevention | Secondary prevention | Financial costs | Future therapies

See also

Notes

References

  • CDC, Division of Parasitic Diseases. Chagas Disease Fact Sheet. (23 September 2004). Accessed 24 September 2006.
  • Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Arjona-Torres A, Ramirez-Sierra M (2004). "Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice". Infect Immun. 72 (1): 46–53. PMID 14688079.
  • CDC, Division of Parasitic Diseases.Chagas Disease(23 October 2007). Accessed 16 August 2007.
  • CDC, Division of Parasitic Diseases.Chagas Disease Epidemiology.(23 October 2007). Accessed 16 August 2007.
  • CDC, Division of Parasitic Diseases. Treatment(23 October 2007). Accessed 16 August 2007.

Further reading

External links

Recent news and events

Template:Protozoal diseases Template:Link FA ar:شاجاس ca:Malaltia de Chagas de:Chagas-Krankheit it:Malattia di Chagas lt:Čagaso liga ms:Penyakit Cagas nl:Ziekte van Chagas sv:Chagas sjukdom


Template:WikiDoc Sources